M

Myriad Genetics
D

MYGN

15.460
USD
0.34
(2.25%)
Market Closed
Volume
24,354
EPS
0
Div Yield
-
P/E
-12
Market Cap
1,407,404,656
OverviewSignalsIdeasNews
Related Instruments
    BDX
    BDX
    -2.040
    (-0.90%)
    225.190 USD
    D
    DGX
    3.615
    (2.30%)
    160.455 USD
    H
    HOLX
    1.040
    (1.34%)
    78.600 USD
    I
    ILMN
    -7.180
    (-5.05%)
    135.110 USD
    L
    LH
    -3.029
    (-1.27%)
    235.180 USD
    TMO
    TMO
    -19.95
    (-3.74%)
    513.04 USD
    More
News

Title: Myriad Genetics

Sector: Healthcare
Industry: Diagnostics & Research
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarkerdiscovery and companion diagnostic services to pharma and biotech companies.